Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

Neuropsychopharmacology

Volumn 30, Issue 11, 2005, Pages 1963-1985

  Depoortère, Ronan ^a   Dargazanli, Gihad ^a   Estenne Bouhtou, Genevieve ^a   Coste, Annick ^a   Lanneau, Christophe ^a   Desvignes, Christophe ^a   Poncelet, Martine ^a   Heaulme, Michel ^a   Santucci, Vincent ^a   Decobert, Michel ^a   Cudennec, Annie ^a   Voltz, Carolle ^a   Boulay, Denis ^a   Terranova, Jean Paul ^a   Stemmelin, Jeanne ^a   Roger, Pierre ^a   Marabout, Benoit ^a   Sevrin, Mireille ^a   Vigé, Xavier ^a   Biton, Bruno ^a   Steinberg, Régis ^a   Françon, Dominique ^a   Alonso, Richard ^a   Avenet, Patrick ^a   Oury Donat, Florence ^a   Perrault, Ghislaine ^a   Griebel, Guy ^a   George, Pascal ^a   Soubrié, Philippe ^a   Scatton, Bernard ^a   more..

^a SANOFI   (France)

Author keywords

Antidepressant anxiolytic; Atypical antipsychotic; GlyT1 inhibitor; Hypoglutamatergy; Schizophrenia

Indexed keywords

ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; DEXAMPHETAMINE; DIZOCILPINE; DOPAMINE; GLYCINE; GLYCINE TRANSPORTER 1; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; PHENCYCLIDINE; PROLACTIN; SSR 504734; TRITIUM; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN CORTEX; BRAIN FUNCTION; BRAIN NERVE CELL; BRAIN SLICE; CATALEPSY; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG POTENCY; DRUG POTENTIATION; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; ENERGY; EVOKED RESPONSE; EX VIVO STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPERACTIVITY; HYPERSENSITIVITY; IC 50; IN VIVO STUDY; LATENT PERIOD; LIMBIC CORTEX; LOCOMOTION; MALE; METABOLIC ACTIVATION; MOTHER; MOUSE; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC INHIBITION; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; REM SLEEP; ROTATION; SCHIZOPHRENIA; STRESS; SYMPTOM;

ACETYLCHOLINE; ACTION POTENTIALS; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN CHEMISTRY; CARBON ISOTOPES; CELLS, CULTURED; CEREBRAL CORTEX; CIRCADIAN RHYTHM; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HIPPOCAMPUS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MOTOR ACTIVITY; NEURAL INHIBITION; NEURONS; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION;

EID: 29744453122     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300772     Document Type: Article

References (86)

1. Allen RM, Young SJ (1978). Phencyclidine-induced psychosis. Am J Psychiatry 135: 1081-1084.
2. Andersen JD, Pouzet B (2004). Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 29: 1080-1090.
3. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI et al (2001). ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60: 1414-1420.
4. Aubrey KR, Vandenberg RJ (2001). N[3-(4′-fluorophenyl)-3-(4′- phenylphenoxy) propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol 134: 1429-1436.
5. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83: 3287-3293.
6. Bergeron R, Meyer TM, Coyle JT, Greene RW (1998). Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95: 15730-15734.
7. Bergink V, van Megen HJGM, Westenberg HGM (2004). Glutamate and anxiety. Eur Neuropsychopharmacol 14: 175-183.
8. Bert L, Robert F, Denoroy L, Stoppini L, Renaud B (1996). Enhanced temporal resolution for the microdialysis monitoring of catecholamines and excitatory amino acids using capillary electrophoresis with laser-induced fluorescence detection. Analytical developments and in vitro validations. J Chromatogr A 755: 99-111.
9. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343.
10. Brébion G, Smith MJ, Gorman JM, Malaspina D, Sharif Z, Amador X (2000). Memory and schizophrenia: differential link of processing speed and selective attention with two levels of encoding. J Psychiatr Res 34: 121-127.
11. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811.
12. Brown A, Carlyle I, Clark J, Hamilton W, Gibson S, McGarry G et al (2001). Discovery and SAR of Org 24598 - a selective glycine uptake inhibitor. Bioorg Med Chem Lett 11: 2007-2009.
13. Carlsson A, Lindqvist M (1963). Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-144.
14. Chen L, Muhlhauser M, Yang CR (2003). Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89: 691-703.
15. Cubelos B, Gimenez C, Zafra F (2005). Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15: 448-459.
16. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 277: 253-264.
17. Dargazanli G, Estenne-Bouhtou G, Magat P, Marabout B, Medaisko F, Roger P et al (2003). Preparation of N-[phenyl(piperidin-2-yl)methyl]benzamides as specific inhibitors of glycine transporters GlyT1 and/or GlyT2. Patent WO2003089411-A1.
18. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998b). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65-75.
19. Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR (1998a). Metabolic mapping of the rat after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787: 181-190.
20. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56: 19-23.
21. Fish EW, Sekinda M, Ferrari PF, Dirks A, Miczek KA (2000). Distress vocalizations in maternally separated mouse pups: modulation via 5-HT(1A), 5-HT(1B) and GABA(A) receptors. Psychopharmacology 149: 277-285.
22. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic Coordinates. Academic Press: San Diego.
23. Gardner CR (1985). Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. J Pharmacol Methods 14: 181-187.
24. Gifford AN, Ashby CR (1996). Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2 and is potentiated by the cannabinoid antagonist, SR141716A. J Pharmacol Exp Ther 277: 1431-1436.
25. Goff DC, Evins AE (1998). Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 6: 59-77.
26. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56: 21-27.
27. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213-1215.
28. Gold PE (2003). Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80: 194-210.
29. Goldman-Rakic PS, Selemon LD (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23: 437-458.
30. Gomeza J, Ohno K, Betz H (2003). Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr Opin Drug Discov Dev 5: 675-682.
31. Gomeza J, Zafra F, Olivares L, Gimenez C, Aragon C (1995). Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells. Biochim Biophys Acta 1233: 41-46.
32. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
33. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P et al (2002). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301: 333-345.
34. Harsing Jr LG, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C et al (2003). The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74: 811-825.
35. Hashimoto A, Oka T (1997). Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 52: 325-353.
36. Heckers S, Konradi C (2002). Hippocampal neurons in schizophrenia. J Neural Transm 109: 891-905.
37. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ (2001). Pharmacological assessment of the role of the glycine transporter Glyt-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 10: 88-96.
38. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159: 480-482.
39. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29-36.
40. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998). Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1: 131-135.
41. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29: 300-307.
42. Javitt DC, Frusciante M (1997). Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology 129: 96-98.
43. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M et al (2001). Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4: 385-391.
44. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
45. Johnson JW, Ascher P (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325: 529-531.
46. Kapur S, Remington G (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
47. Kim KM, Kingsmore SF, Han H, Yang-Feng TL, Godinot N, Seldin MF et al (1994). Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol Pharmacol 45: 608-617.
48. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ et al (2003). The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3- (4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosi 23: 7586-7591.
49. Kleinlogel H (1982). The rat paradoxical sleep as a pharmacological test model. In: Herrmann WM (ed). EEG in Drug Research. Gustave Fisher: Stuttgart. pp 75-88.
50. Konradi C, Heckers S (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97: 153-179.
51. Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R (1999). The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 10: 73-83.
52. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
53. Laruelle M (2000). The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31: 371-384.
54. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL (2003). Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 54: 1162-1170.
55. Lewis R (2004). Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29: 102-113.
56. Lieberman JA, Sheitman BB, Kinon BJ (1997). Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205-229.
57. 3H]-(N-[3-4′fluorophenyl)-3-(4′phenylphenoxy) propyl]) sarcosine. Neuropharmacology 45: 585-593.
58. Martina M, Gorfinkel Y, Halman S, Löwe JA, Periyalwar P, Schmidt CJ et al (2004). Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557: 489-500.
59. McCaughran Jr J, Mahjubi E, Decena E, Hitzemann R (1997). Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology 134: 131-139.
60. B receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 1: 191-213.
61. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE (2000). Effects of ketamine, MK-801 and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropharmacology 22: 400-412.
62. Muir KW, Lees KR (1995). Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513.
63. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z et al (2001). The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology 156: 284-290.
64. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
65. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
66. Poncelet M, Santucci V, Paul R, Gueudet C, Lavastre S, Guitard J et al (1993). Neuropharmacological profile of a novel and selective ligand of the sigma site: SR31742. Neuropharmacology 6: 605-615.
67. Reimherr FW, Wood DR, Wender PH (1986). The use of MK 801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull 22: 237-242.
68. Riedel G, Platt B, Micheau J (2003). Glutamate receptor function in learning and memory. Behav Brain Res 140: 1-47.
69. Rushe TM, Woodruff PW, Murray RM, Morris RG (1999). Episodic memory and learning in patients with chronic schizophrenia. Schizophr Res 35: 85-96.
70. Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572.
71. Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719.
72. Slassi A, Egle I (2004). Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases. Expert Opin Ther Patents 12: 201-214.
73. Slater IH, Jones GT, Moore RA (1978). Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake. Neuropharmacology 17: 383-389.
74. Smith G, Ruhland T, Mikkelsen G, Andersen K, Christoffersen CT, Alifrangis LH et al (2004). The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Bioorg Med Chem Lett 14: 4027-4030.
75. Tamminga CA, Holcomb HH, Gao XM, Lahti AC (1995). Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10(Suppl 3): 29-37.
76. 1A receptor agonist, alleviates disturbances of novelty discrimination in rats, a model of selective attention deficit. Psychopharmacology (in press).
77. Tsai G, Lane H, Young PJ, Lane N, Chong M (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55: 452-456.
78. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998). D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44: 1081-1089.
79. Vandenberg RJ, Aubrey KR (2001). Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 5: 507-518.
80. Vanhoof G, Wetsel WC, Rodriguiz RM, Eldridge M, Berben M, Moechars D et al (2004). Glycine transporter 1 heterozygotes display reduced anxiety in novel environments. Program No. 504.13. 2004 Abstract Viewer/Itinerary Planner Washington, DC: Society for Neuroscience, Online.
81. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7: 9-24.
82. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001). Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107: 535-550.
83. Wang C, McInnis J, West JB, Bao J, Anastasio N, Guidry JA et al (2003). Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J Pharmacol Exp Ther 304: 266-272.
84. Weinberger DR (1986). The pathogenesis of schizophrenia: a neurodevelopmental theory. In: Nasrallah HAW, Weinberger DR (eds). The Neurology of Schizophrenia. Elsevier: Amsterdam, pp 397-406.
85. Wilcox KS, Fitzsimonds RM, Johnson B, Dichter MA (1996). Glycine regulation of synaptic NMDA receptors in hippocampal neurons. J Neurophysiol 76: 3415-3424.
86. Willner P, Muscat R, Papp M (1992). Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16: 525-534.